NOVAN Nitric Oxide-Based Medicine
We use our proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs.
Press Releases
-
June 25, 2020
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
-
June 24, 2020
Novan to Present at Virtual Life Sciences Investor Forum on June 25
-
April 30, 2020
Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
